Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2016 - 2021)

Historic Non-Current Deffered Revenue for Syndax Pharmaceuticals (SNDX) over the last 7 years, with Q2 2021 value amounting to $10.9 million.

  • Syndax Pharmaceuticals' Non-Current Deffered Revenue fell 1225.05% to $10.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $10.9 million, marking a year-over-year decrease of 1225.05%. This contributed to the annual value of $11.6 million for FY2020, which is 1154.34% down from last year.
  • As of Q2 2021, Syndax Pharmaceuticals' Non-Current Deffered Revenue stood at $10.9 million, which was down 1225.05% from $11.2 million recorded in Q1 2021.
  • Syndax Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $16.8 million for Q4 2017, and its period low was $10.9 million during Q2 2021.
  • Its 5-year average for Non-Current Deffered Revenue is $13.6 million, with a median of $13.6 million in 2017.
  • In the last 5 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue soared by 1785.51% in 2017 and then plummeted by 1258.43% in 2018.
  • Over the past 5 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $16.8 million in 2017, then dropped by 12.58% to $14.6 million in 2018, then decreased by 10.35% to $13.1 million in 2019, then dropped by 11.54% to $11.6 million in 2020, then fell by 6.52% to $10.9 million in 2021.
  • Its Non-Current Deffered Revenue was $10.9 million in Q2 2021, compared to $11.2 million in Q1 2021 and $11.6 million in Q4 2020.